215 related articles for article (PubMed ID: 17593021)
1. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
Levenga TH; Timmer-Bonte JN
Br J Haematol; 2007 Jul; 138(2):146-52. PubMed ID: 17593021
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
3. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
Lyman GH; Kuderer NM
Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
[TBL] [Abstract][Full Text] [Related]
4. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
5. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
6. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
8. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
9. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.
Sasse EC; Sasse AD; Brandalise S; Clark OA; Richards S
Cochrane Database Syst Rev; 2005 Jul; (3):CD004139. PubMed ID: 16034921
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
11. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
12. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
Clark OA; Lyman GH; Castro AA; Clark LG; Djulbegovic B
J Clin Oncol; 2005 Jun; 23(18):4198-214. PubMed ID: 15961767
[TBL] [Abstract][Full Text] [Related]
13. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
14. [Colony stimulating factors in chemotherapy induced neutropenic fever].
Sanz Rubiales A; García Alvarez G; Centeno Cortés C; Martín Ortega Y; Del Valle Rivero AL; Nieto Sanz J
An Med Interna; 1998 Feb; 15(2):100-4. PubMed ID: 9542208
[TBL] [Abstract][Full Text] [Related]
15. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
16. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
18. [High risk febrile neutropenia in acute leukemia. The experience of a public hospital. National Program of Antineoplastic Drugs in Adult, Hospital del Salvador, 1991-2001].
Puga B; Puga I; Cabrera ME; Undurraga MS; Guerra C; Urrejola G; Toro P
Rev Med Chil; 2003 Sep; 131(9):1023-30. PubMed ID: 14635589
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]